Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against ...

DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with Hunter syndrome (MPS II).

Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price trimmed by The Goldman Sachs Group from $45.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) – Equities research analysts at Leerink Partnrs decreased their FY2025 EPS estimates for shares of Denali Therapeutics in a research note ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...

Denali Therapeutics Inc. (DNLI) stock price is 23.30 and Denali Therapeutics Inc. (DNLI) 10-day simple moving average is 23.08. Denali Therapeutics Inc. (DNLI) stock price is 23.30 and Denali ...